Anti-SSA status split Sjögren's disease into two biologically different conditions

Design

single-cell RNA sequencing with surface protein profiling, cross-sectional comparative analysis

Population

1.5 million peripheral blood mononuclear cells from 333 participants, stratified by Sjögren's diagnosis and anti-SSA status, with symptomatic non-Sjögren's controls

Primary outcome

peripheral immune cell states and transcriptional signatures by disease subgroup

Effect

anti-SSA-positive participants showed a dominant persistent type I interferon signature with altered transitional B cells (reduced BCR diversity, shorter CDR3); anti-SSA-negative participants differed little from symptomatic controls

Sjögren's disease has always been heterogeneous, and the usual explanation is that it is one disease with variable expression. This study tested the alternative. Single-cell RNA sequencing with surface protein profiling was performed on 1.5 million peripheral blood mononuclear cells from 333 participants, stratified by diagnosis and by anti-SSA antibody status, with symptomatic non-Sjögren's controls for comparison.

Two endotypes emerged. Anti-SSA-positive participants showed a dominant and persistent type I interferon signature with altered immune cell composition. Transitional B cells were the population most affected: altered developmental states, reduced B-cell receptor diversity, shorter CDR3 regions, and more predicted interactions with activated immune cells - a pattern consistent with disturbance of early B-cell selection rather than with downstream activation. Anti-SSA-negative participants, by contrast, showed limited transcriptional difference from symptomatic controls who did not have Sjögren's disease.

That second finding is the uncomfortable one, and it is where the clinical relevance sits. If anti-SSA-negative Sjögren's is transcriptionally indistinguishable from sicca symptoms without the disease, then the label may be doing less work than we assume - which matters because those patients are counselled about lymphoma risk, systemic complications and treatment in the same terms as seropositive patients. This is blood rather than salivary gland, and a cross-sectional comparison rather than a longitudinal one, so it cannot say that the two groups behave differently over time. But it is a large dataset making a specific claim: record the anti-SSA status prominently, and treat it as a statement about disease biology rather than as one diagnostic criterion among several.

• Record anti-SSA status prominently in the problem list, not only in the original diagnostic work-up
• Counsel seropositive and seronegative patients differently on systemic risk, while acknowledging that the evidence base for seronegative disease is weaker than it appears
• Reserve interferon-directed or B-cell-directed approaches and trials for the seropositive group, where the biology supports them
• Reassess the diagnosis in a seronegative patient whose picture is purely sicca - this study found little to distinguish them from symptomatic controls
• Keep salivary gland assessment in the pathway; this was peripheral blood only

Why it matters

It questions whether seronegative Sjögren's disease is the same illness we are treating in seropositive patients.

Don't overread it

Peripheral blood, cross-sectional, with no outcome or treatment-response data - this defines endotypes, not prognoses.

The statistics, in plain English

This is a descriptive, cross-sectional comparison: 333 participants is large for single-cell work but says nothing about how either group changes over time or responds to treatment. The comparator being symptomatic non-Sjögren's controls rather than healthy volunteers is a real strength, because it tests whether the diagnosis adds anything beyond having the symptoms. The absence of detected transcriptional difference in the seronegative group is not proof of no difference - blood may simply be the wrong tissue in which to look for it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.